MUMBAI, India, Feb. 6 -- Intellectual Property India has published a patent application (202511131983 A) filed by Panipat Institute Of Engineering And Technology, Samalkha, Haryana, on Dec. 26, 2025, for 'tumor microenvironment-activated antibody-drug conjugates employing selectively cleavable linkers for targeted cancer therapy.'
Inventor(s) include Prof. Parveen Kumar Goyal; Dr. Preeti Garg; and Dr. Gaurav Agarwal.
The application for the patent was published on Feb. 6, under issue no. 06/2026.
According to the abstract released by the Intellectual Property India: "The present invention discloses tumor microenvironment-activated antibody-drug conjugates comprising an antibody or antigen-binding fragment, a cytotoxic or therapeutic payload, and a selectively cleavable linker that responds to tumor-specific biochemical or physicochemical cues such as enzymatic activity, acidic pH, redox potential, or hypoxia. The conjugates remain stable in systemic circulation and release the payload upon localization within tumor tissue, thereby enhancing therapeutic efficacy while minimizing systemic toxicity. The disclosed platform is versatile, allowing customization of antibodies, linkers, and payloads for a wide range of cancer types, and provides a robust strategy for targeted, controlled, and safe cancer therapy."
Disclaimer: Curated by HT Syndication.
